Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification

Danielle D. Elliott, Steven I. Sherman, Naifa L. Busaidy, Michelle D. Williams, Libero Santarpia, Gary L. Clayman, Adel K. El-Naggar

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Anaplastic thyroid carcinoma is a rare and universally fatal disease. Therefore, novel biomarkers are needed as surrogate end points in triaging patients for novel and selective biologic treatments. Up-regulation of several growth factor receptors has been shown to be associated with the biologic progression and response to targeted therapy of several malignancies. To determine the role of growth factor receptors in the biologic stratification of anaplastic thyroid carcinoma, we studied the expression of epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor β, and HER-2 receptor in a large cohort of anaplastic thyroid carcinomas by immunohistochemical techniques. The percentage of positive cells, staining intensity and localization of staining in the anaplastic component, and coexisting well-differentiated thyroid carcinoma and adjacent nonneoplastic thyroid were evaluated for these markers. EGFR, platelet-derived growth factor receptor β, and HER-2 were overexpressed in 58%, 16%, and 16% of anaplastic carcinomas, respectively. In tumors with adjacent normal thyroid parenchyma and/or differentiated carcinoma components, overexpression of all 3 markers was noted exclusively in the anaplastic component. Mutational analysis of exons 18, 19, and 21 of the EGFR gene showed no mutations in all anaplastic carcinomas. We conclude that the expression of these markers (1) may play a role in a subset of thyroid tumorigenesis and anaplastic transformation and (2) can be validated for potential use in the stratification of patients for targeted therapy.

Original languageEnglish
Pages (from-to)15-20
Number of pages6
JournalHuman Pathology
Volume39
Issue number1
DOIs
Publication statusPublished - Jan 2008

Fingerprint

Growth Factor Receptors
Platelet-Derived Growth Factor Receptors
Thyroid Gland
Carcinoma
Epidermal Growth Factor Receptor
Biomarkers
Staining and Labeling
erbB-1 Genes
Thyroid Neoplasms
Exons
Neoplasms
Carcinogenesis
Up-Regulation
Therapeutics
Mutation
Anaplastic Thyroid Carcinoma

Keywords

  • Anaplastic thyroid carcinoma
  • EGFR
  • Growth factors
  • HER-2
  • PDGFR
  • Targeted therapy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Growth factor receptors expression in anaplastic thyroid carcinoma : potential markers for therapeutic stratification. / Elliott, Danielle D.; Sherman, Steven I.; Busaidy, Naifa L.; Williams, Michelle D.; Santarpia, Libero; Clayman, Gary L.; El-Naggar, Adel K.

In: Human Pathology, Vol. 39, No. 1, 01.2008, p. 15-20.

Research output: Contribution to journalArticle

Elliott, Danielle D. ; Sherman, Steven I. ; Busaidy, Naifa L. ; Williams, Michelle D. ; Santarpia, Libero ; Clayman, Gary L. ; El-Naggar, Adel K. / Growth factor receptors expression in anaplastic thyroid carcinoma : potential markers for therapeutic stratification. In: Human Pathology. 2008 ; Vol. 39, No. 1. pp. 15-20.
@article{bdd0edbc5e8047dd9869ff6e715147c7,
title = "Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification",
abstract = "Anaplastic thyroid carcinoma is a rare and universally fatal disease. Therefore, novel biomarkers are needed as surrogate end points in triaging patients for novel and selective biologic treatments. Up-regulation of several growth factor receptors has been shown to be associated with the biologic progression and response to targeted therapy of several malignancies. To determine the role of growth factor receptors in the biologic stratification of anaplastic thyroid carcinoma, we studied the expression of epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor β, and HER-2 receptor in a large cohort of anaplastic thyroid carcinomas by immunohistochemical techniques. The percentage of positive cells, staining intensity and localization of staining in the anaplastic component, and coexisting well-differentiated thyroid carcinoma and adjacent nonneoplastic thyroid were evaluated for these markers. EGFR, platelet-derived growth factor receptor β, and HER-2 were overexpressed in 58{\%}, 16{\%}, and 16{\%} of anaplastic carcinomas, respectively. In tumors with adjacent normal thyroid parenchyma and/or differentiated carcinoma components, overexpression of all 3 markers was noted exclusively in the anaplastic component. Mutational analysis of exons 18, 19, and 21 of the EGFR gene showed no mutations in all anaplastic carcinomas. We conclude that the expression of these markers (1) may play a role in a subset of thyroid tumorigenesis and anaplastic transformation and (2) can be validated for potential use in the stratification of patients for targeted therapy.",
keywords = "Anaplastic thyroid carcinoma, EGFR, Growth factors, HER-2, PDGFR, Targeted therapy",
author = "Elliott, {Danielle D.} and Sherman, {Steven I.} and Busaidy, {Naifa L.} and Williams, {Michelle D.} and Libero Santarpia and Clayman, {Gary L.} and El-Naggar, {Adel K.}",
year = "2008",
month = "1",
doi = "10.1016/j.humpath.2007.05.012",
language = "English",
volume = "39",
pages = "15--20",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Growth factor receptors expression in anaplastic thyroid carcinoma

T2 - potential markers for therapeutic stratification

AU - Elliott, Danielle D.

AU - Sherman, Steven I.

AU - Busaidy, Naifa L.

AU - Williams, Michelle D.

AU - Santarpia, Libero

AU - Clayman, Gary L.

AU - El-Naggar, Adel K.

PY - 2008/1

Y1 - 2008/1

N2 - Anaplastic thyroid carcinoma is a rare and universally fatal disease. Therefore, novel biomarkers are needed as surrogate end points in triaging patients for novel and selective biologic treatments. Up-regulation of several growth factor receptors has been shown to be associated with the biologic progression and response to targeted therapy of several malignancies. To determine the role of growth factor receptors in the biologic stratification of anaplastic thyroid carcinoma, we studied the expression of epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor β, and HER-2 receptor in a large cohort of anaplastic thyroid carcinomas by immunohistochemical techniques. The percentage of positive cells, staining intensity and localization of staining in the anaplastic component, and coexisting well-differentiated thyroid carcinoma and adjacent nonneoplastic thyroid were evaluated for these markers. EGFR, platelet-derived growth factor receptor β, and HER-2 were overexpressed in 58%, 16%, and 16% of anaplastic carcinomas, respectively. In tumors with adjacent normal thyroid parenchyma and/or differentiated carcinoma components, overexpression of all 3 markers was noted exclusively in the anaplastic component. Mutational analysis of exons 18, 19, and 21 of the EGFR gene showed no mutations in all anaplastic carcinomas. We conclude that the expression of these markers (1) may play a role in a subset of thyroid tumorigenesis and anaplastic transformation and (2) can be validated for potential use in the stratification of patients for targeted therapy.

AB - Anaplastic thyroid carcinoma is a rare and universally fatal disease. Therefore, novel biomarkers are needed as surrogate end points in triaging patients for novel and selective biologic treatments. Up-regulation of several growth factor receptors has been shown to be associated with the biologic progression and response to targeted therapy of several malignancies. To determine the role of growth factor receptors in the biologic stratification of anaplastic thyroid carcinoma, we studied the expression of epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor β, and HER-2 receptor in a large cohort of anaplastic thyroid carcinomas by immunohistochemical techniques. The percentage of positive cells, staining intensity and localization of staining in the anaplastic component, and coexisting well-differentiated thyroid carcinoma and adjacent nonneoplastic thyroid were evaluated for these markers. EGFR, platelet-derived growth factor receptor β, and HER-2 were overexpressed in 58%, 16%, and 16% of anaplastic carcinomas, respectively. In tumors with adjacent normal thyroid parenchyma and/or differentiated carcinoma components, overexpression of all 3 markers was noted exclusively in the anaplastic component. Mutational analysis of exons 18, 19, and 21 of the EGFR gene showed no mutations in all anaplastic carcinomas. We conclude that the expression of these markers (1) may play a role in a subset of thyroid tumorigenesis and anaplastic transformation and (2) can be validated for potential use in the stratification of patients for targeted therapy.

KW - Anaplastic thyroid carcinoma

KW - EGFR

KW - Growth factors

KW - HER-2

KW - PDGFR

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=36748999952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36748999952&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2007.05.012

DO - 10.1016/j.humpath.2007.05.012

M3 - Article

C2 - 17949783

AN - SCOPUS:36748999952

VL - 39

SP - 15

EP - 20

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 1

ER -